Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | AKT1 | P31749 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | PRKCG | P05129 | 1/20 | 0.69 |
| ▸ | PRKCB | P05771 | 1/20 | 0.69 |
| ▸ | PRKCA | P17252 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 1/20 | 0.69 |
| ▸ | PRKCI | P41743 | 1/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10415264 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL20769827 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL596694 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL26215 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Octadecylphosphonocholine SCHEMBL744376 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Tetradecylphosphocholine SCHEMBL5481590 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL29465558 | 1.00 | LMNA (1.00) | LMNAAKT1ESR1ADORA3CDC25A | |
| Miltefosine SCHEMBL7189058 | 0.98 | LMNA (0.97) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL9234856 | 0.98 | LMNA (0.96) | LMNAAKT1ESR1ADORA3CDC25A | |
| SCHEMBL10934123 | 0.94 | LMNA (0.88) | LMNAAKT1ESR1ADORA3CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106573-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | AMGEN INC. | 2022-04-07 | — | — | US | claimed |
| EP-3941928-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | Amgen Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-113412270-A | Alternative detergents for virus inactivation | 安进公司 | 2021-09-17 | — | — | CN | claimed |
| WO-2020190985-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | AMGEN INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20250283819-A1 | RAPID PATHOLOGY/CYTOLOGY WITHOUT WASH | ESSENLIX CORPORATION (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250249453-A1 | SYSTEMS AND METHODS FOR SERIAL FLOW EMULSION PROCESSES | DROPWORKS, INC. | 2025-08-07 | — | — | US | disclosed |
| CN-113412270-B | Alternative detergents for viral inactivation | 安进公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118852319-A | Alternative detergents for viral inactivation | 安进公司 | 2024-10-29 | — | — | CN | disclosed |
| US-11413297-B2 | Therapies for treating and preventing chronic rhinosinusitis | AVANTI POLAR LIPIDS, LLC (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112236218-B | System and method for continuous flow emulsion processing | 滴管公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114341614-A | Rapid pathology/cytology without wash-out | ESSENLIX 公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220106573-A1 | ALTERNATE DETERGENTS FOR VIRAL INACTIVATION | AMGEN INC. | 2022-04-07 | — | — | US | disclosed |
| CN-101868476-A | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK AS | 2010-10-20 | — | — | CN | disclosed |
| CN-101854914-A | Stable formulations of amylin and analogs thereof | NOVO NORDISK AS | 2010-10-06 | — | — | CN | disclosed |
| CN-101842386-A | Truncated GLP-1 derivatives and their therapeutic uses | NOVO NORDISK AS | 2010-09-22 | — | — | CN | disclosed |
| CN-101842109-A | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK AS | 2010-09-22 | — | — | CN | disclosed |
| US-20090192299-A1 | NANOLIPOPROTEIN PARTICLES AND RELATED METHODS AND SYSTEMS FOR PROTEIN CAPTURE, SOLUBILIZATION, AND/OR PURIFICATION | U.S. DEPARTMENT OF ENERGY | 2009-07-30 | — | — | US | disclosed |
| CN-101133082-A | Acylated GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-27 | — | — | CN | disclosed |
| CN-101128214-A | Extended GLP-1 compounds | NOVO NORDISK AS (DK) | 2008-02-20 | — | — | CN | disclosed |
| CN-1824811-A | Liquid dispense method and microarray manufacturing method | SEIKO EPSON CORP (JP) | 2006-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413297-B2 | Therapies for treating and preventing chronic rhinosinusitis | FPR1, CFTR, FPR3 | LMNA 3383/4885AKT1 1787/4885ESR1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.